

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Young et al.	Confirmation No.:	4680
Serial No:	10/585,772	Art Unit:	1635
371 (c) Date:	November 13, 2007	Examiner:	Shin, Dana H.
Customer No.:	21559		
Title:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER		

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Copies of search reports from corresponding international applications are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action following the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: May 21, 2010

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045